LBT Innovations (ASX:LBT) share price plummets 14% despite positive update

The company's shares are off to a bad start this week…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The LBT Innovations Limited (ASX: LBT) share price is deep in the red today. This comes regardless of the medical technology company providing investors with a positive update yesterday.

At the time of writing, LBT Innovations shares are down a sizeable 14.29% to 12 cents apiece.

doctor looks out window resting head in hand

Image source: Getty Images

What did LBT Innovations announce?

According to its announcement, LBT Innovations advised Clever Culture Systems (CCS) has signed an exclusive distribution agreement with Thermo Fisher Scientific.

CCS is a joint-venture company owned equally by LBT Innovations and German medical equipment group Hettich.

Thermo Fisher is a leading provider of instrumentation and consumables in the US microbiology market.

The 5-year deal will see Thermo Fisher become the exclusive distributor for the company's automated culture plate reader, APAS Independence, in the US.

APAS Independence is the first and only FDA-cleared automated culture plate reader available in the United States. The innovative technology uses advanced imaging and artificial intelligence to interpret bacterial growth on culture plates.

Under the agreement, Thermo Fisher will engage in sales and marketing activities for APAS Independence in the US. In addition, the company will also provide installation, maintenance and support services to customers.

The agreement is a major milestone for LBT Innovations as it will provide sales and commercial activities in the US market which is the largest in the world. It offers more than 1,500 target laboratories for the potential placement of APAS Independence readers.

LBT Innovations CEO and managing director Brent Barnes commented:

This is a really important milestone for LBT and represents a major step forward in our commercialisation strategy in the United States.

We have spoken previously about the importance of appointing well recognised, leading distributors to support our sales efforts in key markets. Thermo Fisher is a leader in microbiology that is recognised globally, and we will benefit greatly from the depth and strength of their sales team in the United States…

We are very pleased to now have two of the world's largest microbiology companies selling our technology across the two main markets of the United States and Europe, which is a further validation of benefits of our technology.

LBT Innovations share price summary

Since the beginning of the year, LBT Innovations shares have moved in circles, remaining relatively unchanged for the period. When zooming out to the last 12 months, however, its shares are down around 8%.

LBT Innovations presides a market capitalisation of roughly $33 million and has over 289 million shares on its books.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A group of people push and shove through the doors of a store, trying to beat the crowd.
Share Market News

Investors are buying CSL shares again. Should you?

Some experts believe that 2026 could mark the low point for the biotech company.

Read more »

A group of young people celebrate and party outside.
Healthcare Shares

If I'd invested $5,000 in 4DMedical shares 12 months ago, guess how much I'd have now!

Can the company's share price keep accelerating even higher? Here's what analysts tip for the next 12 months.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 reasons I'd buy CSL shares in FY27

It still needs to rebuild trust, but lower expectations and several recovery levers make the shares worth considering.

Read more »

Ecstatic man giving a fist pump in an office hallway.
Healthcare Shares

CSL shares jump 15%: Is it time to start buying the beaten-down biotech stock?

CSL shares have climbed 7% higher over the past week alone.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Why is this ASX biotech rocketing more than 20%?

A deal potentially worth hundreds of millions has been struck.

Read more »

Young girl shows hearing aid while smiling.
Healthcare Shares

3 reasons to buy Cochlear shares in June

After a brutal sell-off, the stock may be gearing up for a recovery.

Read more »

patient with doctor, medical company, medical insurance
Cheap Shares

CSL shares trade at just 12 times forecast earnings. Here's why they could be the buy of the decade

The ASX 200 healthcare giant is down more than 60% since August 2025.

Read more »

Falling pills in a blue background.
Healthcare Shares

Sigma Healthcare shares are surging. What does Macquarie say they're worth?

A possible deal has fallen over, which investors appear to like.

Read more »